340 related articles for article (PubMed ID: 36042167)
1. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
Schwach J; Abdellatif M; Stengl A
Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
3. Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry.
Fujii T; Matsuda Y
Expert Opin Biol Ther; 2023; 23(11):1053-1065. PubMed ID: 37953519
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
5. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
6. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
Chia CSB
ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
[TBL] [Abstract][Full Text] [Related]
8. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
9. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
10. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
[TBL] [Abstract][Full Text] [Related]
13. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
14. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
15. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
16. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
Jiang M; Li Q; Xu B
Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
[TBL] [Abstract][Full Text] [Related]
18. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
20. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
